Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics發佈了PRT2527作爲單藥及與Zanubrutinib聯合治療復發/難治性淋巴惡性腫瘤患者的1期劑量遞增研究初步結果